Paula Jiménez-Fonseca1, Alberto Carmona-Bayonas2, Maria Luisa Sánchez Lorenzo3, Javier Gallego Plazas4, Ana Custodio5, Raquel Hernández6, Marcelo Garrido7, Teresa García2, Isabel Echavarría8, Juana María Cano9, Alberto Rodríguez Palomo10, Monserrat Mangas11, Ismael Macías Declara12, Avinash Ramchandani13, Laura Visa14, Antonio Viudez15, Elvira Buxó16, Asunción Díaz-Serrano17, Carlos López18, Aitor Azkarate19, Federico Longo20, Eduardo Castañón21, Rodrigo Sánchez Bayona21, Paola Pimentel22, Maria Luisa Limón23, Paula Cerdá24, Renata Álvarez Llosa25, Raquel Serrano26, Maria Pilar Felices Lobera27, María Alsina28, Alicia Hurtado Nuño29, Carlos Gómez-Martin17. 1. Medical Oncology Department, Hospital Universitario Central de Asturias, Avenida de Roma s/n, 33011, Oviedo, Spain. palucaji@hotmail.com. 2. Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain. 3. Medical Oncology Department, Hospital Universitario Central de Asturias, Avenida de Roma s/n, 33011, Oviedo, Spain. 4. Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain. 5. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain. 6. Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain. 7. Medical Oncology Department, Pontificia Universidad Católica de Chile, Santiago De Chile, Chile. 8. Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. 9. Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. 10. Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain. 11. Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain. 12. Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain. 13. Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain. 14. Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain. 15. Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. 16. Medical Oncology Department, Hospital Clínic, Barcelona, Spain. 17. Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain. 18. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 19. Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain. 20. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. 21. Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain. 22. Medical Oncology Department, Hospital Santa Lucía, Cartagena, Spain. 23. Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain. 24. Medical Oncology Department, Instituto Oncológico Teknon, Barcelona, Spain. 25. Medical Oncology Department, Complejo Hospitalario de Orense, Ourense, Spain. 26. Medical Oncology Department, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain. 27. Medical Oncology Department, Hospital Universitario Miguel Servet de Zaragoza, Zaragoza, Spain. 28. Medical Oncology Department, Hospital Universitario Vall d'Hebron and VHIO-Vall d'Hebron Institute of Oncology, Barcelona, Spain. 29. Medical Oncology Department, Hospital Universitario Fundación Alcorcon, Madrid, Spain.
Abstract
BACKGROUND: Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. METHODS: This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. RESULTS: The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. CONCLUSION: Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.
BACKGROUND:Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. METHODS: This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. RESULTS: The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. CONCLUSION:Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.
Authors: Taroh Satoh; Yung-Jue Bang; Evgeny A Gotovkin; Yasuo Hamamoto; Yoon-Koo Kang; Vladimir M Moiseyenko; Atsushi Ohtsu; Eric Van Cutsem; Nedal Al-Sakaff; Alexa Urspruch; Julie Hill; Harald A Weber; Hyun-Cheol Chung Journal: Oncologist Date: 2014-06-20
Authors: Angela N Bartley; Jessi Christ; Patrick L Fitzgibbons; Stanley R Hamilton; Sanjay Kakar; Manish A Shah; Laura H Tang; Megan L Troxell Journal: Arch Pathol Lab Med Date: 2014-10-02 Impact factor: 5.534
Authors: Josef Rüschoff; Wedad Hanna; Michael Bilous; Manfred Hofmann; Robert Y Osamura; Frédérique Penault-Llorca; Marc van de Vijver; Giuseppe Viale Journal: Mod Pathol Date: 2012-01-06 Impact factor: 7.842
Authors: K Sakai; S Mori; T Kawamoto; S Taniguchi; O Kobori; Y Morioka; T Kuroki; K Kano Journal: J Natl Cancer Inst Date: 1986-11 Impact factor: 13.506
Authors: A Tokunaga; M Onda; T Okuda; T Teramoto; I Fujita; T Mizutani; T Kiyama; T Yoshiyuki; K Nishi; N Matsukura Journal: Cancer Date: 1995-03-15 Impact factor: 6.860
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; A Custodio; M Sánchez Cánovas; R Hernández; C Pericay; I Echavarria; A Lacalle; L Visa; A Rodríguez Palomo; M Mangas; J M Cano; E Buxo; F Álvarez-Manceñido; T García; J E Lorenzo; M Ferrer-Cardona; A Viudez; A Azkarate; A Ramchandani; D Arias; F Longo; C López; R Sánchez Bayona; M L Limón; A Díaz-Serrano; A Fernández Montes; P Sala; P Cerdá; F Rivera; J Gallego Journal: Gastric Cancer Date: 2017-04-09 Impact factor: 7.370
Authors: Sena Valcarcel; Javier Gallego; Paula Jimenez-Fonseca; Marc Diez; Eva Martínez de Castro; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Ana Fernández Montes; Ismael Macias; Laura Visa; Aitana Calvo; Rosario Vidal Tocino; Nieves Martínez Lago; María Luisa Limón; Mónica Granja; Mireia Gil; Paola Pimentel; Lola Macia-Rivas; Carolina Hernández Pérez; Montserrat Mangas; Alfonso Martín Carnicero; Paula Cerdà; Lucía Gomez Gonzalez; Francisco Garcia Navalon; Mª Dolores Mediano Rambla; Marta Martin Richard; Alberto Carmona-Bayonas Journal: J Cancer Res Clin Oncol Date: 2022-08-30 Impact factor: 4.322
Authors: J Gallego Plazas; A Arias-Martinez; A Lecumberri; E Martínez de Castro; A Custodio; J M Cano; R Hernandez; A F Montes; I Macias; A Pieras-Lopez; M Diez; L Visa; R V Tocino; N Martínez Lago; M L Limón; M Gil; P Pimentel; M Mangas; M Granja; A M Carnicero; C Hernández Pérez; L G Gonzalez; P Jimenez-Fonseca; A Carmona-Bayonas Journal: ESMO Open Date: 2022-06-14
Authors: A Viúdez; A Carmona-Bayonas; J Gallego; A Lacalle; R Hernández; J M Cano; I Macías; A Custodio; E Martínez de Castro; A Sánchez; L Iglesia; P Reguera; L Visa; A Azkarate; M Sánchez-Cánovas; M Mangas; M L Limón; A Martínez-Torrón; E Asensio; A Ramchandani; A Martín-Carnicero; A Hurtado; P Cerdà; M Garrido; R Sánchez-Bayonas; R Serrano; P Jiménez-Fonseca Journal: Clin Transl Oncol Date: 2019-08-05 Impact factor: 3.405
Authors: A Custodio; A Carmona-Bayonas; P Jiménez-Fonseca; M L Sánchez; A Viudez; R Hernández; J M Cano; I Echavarria; C Pericay; M Mangas; L Visa; E Buxo; T García; A Rodríguez Palomo; F Álvarez Manceñido; A Lacalle; I Macias; A Azkarate; A Ramchandani; A Fernández Montes; C López; F Longo; R Sánchez Bayona; M L Limón; A Díaz-Serrano; A Hurtado; R Madero; C Gómez; J Gallego Journal: Br J Cancer Date: 2017-05-02 Impact factor: 7.640
Authors: Paula Jiménez Fonseca; Alberto Carmona-Bayonas; Raquel Hernández; Ana Custodio; Juana Maria Cano; Alejandra Lacalle; Isabel Echavarria; Ismael Macias; Monserrat Mangas; Laura Visa; Elvira Buxo; Felipe Álvarez Manceñido; Antonio Viudez; Carles Pericay; Aitor Azkarate; Avinash Ramchandani; Carlos López; Eva Martinez de Castro; Ana Fernández Montes; Federico Longo; Rodrigo Sánchez Bayona; Maria Luisa Limón; Asun Diaz-Serrano; Alfonso Martin Carnicero; David Arias; Paula Cerdà; Fernando Rivera; Jose Maria Vieitez; Manuel Sánchez Cánovas; M Garrido; J Gallego Journal: Br J Cancer Date: 2017-08-01 Impact factor: 7.640
Authors: Almudena Cotes Sanchís; Javier Gallego; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Gema Aguado; Ismael Macias; Carlos Lopez; Flora López; Laura Visa; Marcelo Garrido; Nieves Martínez Lago; Ana Fernández Montes; María Luisa Limón; Aitor Azkárate; Paola Pimentel; Pablo Reguera; Avinash Ramchandani; Juan Diego Cacho; Alfonso Martín Carnicero; Mónica Granja; Marta Martín Richard; Carolina Hernández Pérez; Alicia Hurtado; Olbia Serra; Elvira Buxo; Rosario Vidal Tocino; Paula Jimenez-Fonseca; Alberto Carmona-Bayonas Journal: PLoS One Date: 2020-07-31 Impact factor: 3.240
Authors: David Zaragoza-Huesca; Pedro Garrido-Rodríguez; Paula Jiménez-Fonseca; Eva Martínez de Castro; Manuel Sánchez-Cánovas; Laura Visa; Ana Custodio; Ana Fernández-Montes; Julia Peñas-Martínez; Patricia Morales Del Burgo; Javier Gallego; Ginés Luengo-Gil; Vicente Vicente; Irene Martínez-Martínez; Alberto Carmona-Bayonas Journal: Biomedicines Date: 2022-01-11